Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.verified

0HF9.L

Amicus Therapeutics, a biotechnology enterprise, is committed to the research, development, and commercialization of therapeutic solutions for rare genetic conditions. Its flagship commercial product, Galafold, is a precise, orally administered medication intended for adult patients with a verified diagnosis of Fabry disease who possess a treatable galactosidase alpha gene variant, as indicated by in vitro laboratory assays. The company's robust development pipeline features AT-GAA, an innovative therapeutic approach for Pompe disease, in addition to other enzyme replacement therapies targeting this same condition. Amicus is also conducting a Phase 1/2 clinical trial for CLN3, which is asses...[Read more]

Industry

Medical - Pharmaceuticals

IPO Date

2018-01-29

Stock Exchange

LSE

Ticker

0HF9.L

The PE Ratio as of June 2026 (TTM) for Amicus Therapeutics, Inc. (0HF9.L) is -17.56

According to Amicus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -17.56. This represents a change of -110.99% compared to the average of 159.76 of the last 4 quarters.

Amicus Therapeutics, Inc. (0HF9.L) Historical PE Ratio (quarterly & annually)

How has 0HF9.L PE Ratio performed in the past?

The mean historical PE Ratio of Amicus Therapeutics, Inc. over the last ten years is -31.25. The current -17.56 PE Ratio has changed 5.52% with respect to the historical average. Over the past ten years (40 quarters), 0HF9.L's PE Ratio was at its highest in in the December 2025 quarter at 650.97. The PE Ratio was at its lowest in in the September 2024 quarter at -120.90.

Quarterly (TTM)
Annual

Average

-31.25

Median

-13.72

Minimum

-161.97

Maximum

-3.34

Amicus Therapeutics, Inc. (0HF9.L) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Amicus Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 228.58%

Maximum Annual PE Ratio = -3.34

Minimum Annual Increase = -58.62%

Minimum Annual PE Ratio = -161.97

Quarterly (TTM)
Annual
YearPE RatioChange
2025-161.97216.95%
2024-51.1084.95%
2023-27.6385.20%
2022-14.9219.19%
2021-12.52-42.03%
2020-21.59228.58%
2019-6.5728.84%
2018-5.10-34.37%
2017-7.77132.70%
2016-3.34-58.62%

Amicus Therapeutics, Inc. (0HF9.L) Average PE Ratio

How has 0HF9.L PE Ratio performed in the past?

The current PE Ratio of Amicus Therapeutics, Inc. (0HF9.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-80.24

5-year avg

-53.63

10-year avg

-31.25

Amicus Therapeutics, Inc. (0HF9.L) PE Ratio vs. Peers

How is 0HF9.L’s PE Ratio compared to its peers?

Amicus Therapeutics, Inc.’s PE Ratio is less than Sarepta Therapeutics, Inc. (25.64), less than Agios Pharmaceuticals, Inc. (-3.91), less than Perrigo Company plc (-0.85), greater than Supernus Pharmaceuticals, Inc. (-90.72), less than DENTSPLY SIRONA Inc. (-3.33), less than uniQure N.V. (-7.95), less than OPKO Health, Inc. (-5.13), less than Intellia Therapeutics, Inc. (-3.87), less than Viridian Therapeutics, Inc. (-4.62), less than Nektar Therapeutics (-8.80),

Build a custom stock screener for Amicus Therapeutics, Inc. (0HF9.L) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Amicus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Amicus Therapeutics, Inc. (0HF9.L) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Amicus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Amicus Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Amicus Therapeutics, Inc. (0HF9.L)?

What is the highest PE Ratio for Amicus Therapeutics, Inc. (0HF9.L)?

What is the 3-year average PE Ratio for Amicus Therapeutics, Inc. (0HF9.L)?

What is the 5-year average PE Ratio for Amicus Therapeutics, Inc. (0HF9.L)?

How does the current PE Ratio for Amicus Therapeutics, Inc. (0HF9.L) compare to its historical average?